Goal of this project is to rapidly develop and test antivirals against novel SARS-CoV2. We will measure reductions in virus induced cytopathic effects following different treatments. These treatments will range from the examination of repurposed FDA-approved drugs to novel formulations developed by collaborators at ISU and beyond.